论著

新型冠状病毒感染后儿童多系统炎症综合征2例并文献复习

  • 王思源 ,
  • 王利 ,
  • 温新然 ,
  • 李小青
展开
  • 1.西安医学院,陕西 西安 710068
    2.西安交通大学附属儿童医院 风湿免疫科,陕西 西安 710003
李小青,Email:xa_lxq@163.com

收稿日期: 2023-05-29

  网络出版日期: 2024-01-30

Multisystem inflammatory syndrome in children after severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection: Two cases report and literature review

  • Wang Siyuan ,
  • Wang Li ,
  • Wen Xinran ,
  • Li Xiaoqing
Expand
  • 1. Xi’an Medical University,Xi'an 710068,China
    2. Department of Rheumatology and Immunology,Affiliated Children's Hospital ofXi'anJiaotong University,Xi'an 710003,China

Received date: 2023-05-29

  Online published: 2024-01-30

摘要

目的 探讨儿童多系统炎症综合征(multisystem inflammatory syndrome in children,MIS-C)的临床特征及诊治要点。方法 回顾性分析西安交通大学附属儿童医院风湿免疫科收治的2例MIS-C患儿相关临床资料,并复习相关文献。结果 2例患儿男女各1例,男性患儿2岁1月龄,女性患儿3岁8月龄,发病4周前均有新型冠状病毒感染史,病初以川崎病样症状为主要临床表现,病程中累及消化、循环、血液、呼吸等多个系统,其中1例累及神经系统;并结合实验室检查最终诊断MIS-C。2例患儿均接受静脉注射人免疫球蛋白及糖皮质激素治疗,其中1例因病情进展行连续性血液净化及无创呼吸机辅助通气治疗,预后均良好。结论 对于近期有新型冠状病毒感染,出现类似川崎病症状,则应考虑MIS-C的可能,该疾病进展快且易并发多系统受累,需早识别、早干预,以改善预后。

本文引用格式

王思源 , 王利 , 温新然 , 李小青 . 新型冠状病毒感染后儿童多系统炎症综合征2例并文献复习[J]. 临床荟萃, 2023 , 38(12) : 1112 -1116 . DOI: 10.3969/j.issn.1004-583X.2023.12.010

Abstract

Objective To explore the clinical features and key points of diagnosis and treatment of multisystem inflammatory syndrome in children (MIS-C). Methods The clinical data of two children with MIS-C diagnosed and treated in the Department of Rheumatology and Immunology of XJTU Affiliated Children's Hospital were retrospectively analyzed and the relevant literature was reviewed. Results There were two patients (1 male and 1 female), the age of male was 2 years and 1 month, and the age of female was 3 years and 8 months. Both had a history of SARS-CoV-2 infection 4 weeks before their illness onset. At the beginning of the disease, Kawasaki Disease-like symptoms were the main clinical manifestations, with multi-system involvement in the course of the disease, including prominent gastrointestinal, cardiac, hematologic and respiratory, and one of them with neurologic symptoms. MIS-C was finally diagnosed according to the results of laboratory examination. All of them were treated with intravenous immunoglobulin and glucocorticoids. One of them was treated with continuous kidney replacement therapy and noninvasive mechanical ventilation due to progressive disease, and both patients had a good prognosis. Conclusion MIS-C should be considered in patients with recent SARS-CoV-2 infection followed by Kawasaki disease-like symptoms. The disease progresses rapidly and involves multiple systems, so early recognition and intervention are needed to improve the prognosis.

参考文献

[1] Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic[J]. Lancet, 2020, 395(10237):1607-8.
[2] Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS)-guidance for clinicians[EB/OL]. https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance. 2020-05-01/2023-02-25.
[3] Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)[EB/OL]. https://emergency.cdc.gov/han/2020/han00432.asp. 2020-05-14/2023-02-25.
[4] Multisystem inflammatory syndrome in children and adolescents with COVID-19[EB/OL]. https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. 2020-05-15/2023-02-25.
[5] Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in us children and adolescents[J]. N Engl J Med, 2020, 383(4):334-346.
[6] Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: Prospective observational study[J]. BMJ, 2020, 369:m2094.
[7] Mamishi S, Movahedi Z, Mohammadi M, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran[J]. Epidemiol Infect, 2020, 148: e196, 1-5.
[8] Chinniah K, Bhimma R, Naidoo K L, et al. Multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection in KwaZulu-Natal, South Africa[J]. Pediatr Infect Dis J, 2023, 42(1): e9-e14.
[9] Kim H, Shim JY, Ko JH, et al. Multisystem inflammatory syndrome in children related to COVID-19: The first case in Korea[J]. Korean Med Sci, 2020, 35(43): e391.
[10] Yamaguchi Y, Takasawa K, Irabu H, et al. Infliximab treatment for refractoryCOVID-19-associated multisystem inflammatory syndrome in a Japanese child[J]. J Infect Chemother, 2022, 28(6): 814-818.
[11] Mishra B, Mishra B, Mohapatra A, et al. Clinical profile and outcomes of multisystem inflammatory syndrome in children: A multicentric observational study[J]. Cureus, 2022, 14(9): e28821.
[12] Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State[J]. N Engl J Med, 2020, 383(4): 347-358.
[13] Lima-Setta F, De Magalhaes-Barbosa MC, Rodrigues-Santos G, et al. Multisystem inflammatory syndrome in children(MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study[J]. Jornal De Pediatria, 2021, 97(3): 354-361.
[14] Valverde I, Singh Y, Sanchez-De-Toledo J, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe[J]. Circulation, 2021, 143(1): 21-32.
[15] Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic[J]. Circulation, 2020, 142(5):429-436.
[16] Feleszko W, Okarska-Napierala M, Buddingh EP, et al. Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI position paper[J]. Pediatr Allergy Immunol, 2023, 34(1): e13900.
[17] Olivotto S, Basso E, Lavatelli R, et al. Acute encephalitis in pediatric multisystem inflammatory syndrome associated with COVID-19[J]. Ur J Paediatr Neuro, 2021, 34: 84-90.
[18] Siracusa L, Cascio A, Giordano S, et al. Neurological complications in pediatric patients with SARS-CoV-2 infection: a systematic review of the literature[J]. Ital J Pediatr, 2021, 47(1):123.
[19] Akcay N, Ogur M, Menentoglu ME, et al. Acute cerebellitis in MIS-C: A case report[J]. Pediatr Infect Dis J, 2022, 41(1): E16-E8.
[20] Ganguly M, Nandi A, Banerjee P, et al. A comparative study of IL-6, CRP and NT-proBNP levels in post-COVID multisystem inflammatory syndrome in children (MISC) and Kawasaki disease patients[J]. Int J Rheum Dis, 2022, 25(1): 27-31.
[21] Kostik MM, Bregel LV, Avrusin IS, et al. Distinguishing between multisystem inflammatory syndrome, associated with covid-19 in children and the Kawasaki disease: Development of preliminary criteria based on the data of the retrospective multicenter cohort study[J]. Front Pediatr, 2021, 9: 787353.
[22] Henderson LA, Canna SW, Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3[J]. Arthritis Rheumatol, 2022, 74(4): E1-E20.
[23] Bottari G, Severini F, Markowich AH, et al. Hemoadsorption for severe MIS-C in critically ill children, should we consider it as a therapeutic opportunity?[J]. Int J Artif Organs, 2022, 45(10): 871-877.
[24] Lalwani P, Baskaran S, Uribe DA, et al. A Case of COVID-19-associated pediatric multisystem inflammatory syndrome in shock managed by cytokine filtration[J]. Case Rep Pediatr, 2022: 3373289.
[25] Jiang L, Tang K, Irfan O, et al. Epidemiology, clinical features, and outcomes of multisystem inflammatory syndrome in children (MIS-C) and adolescents-a live systematic review and meta-analysis[J]. Curr Pediatr Rep, 2022, 10(2): 19-30.
文章导航

/